Article info

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Authors

  1. Correspondence to Dr Lars Erik Kristensen, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark; lars.erik.kristensen{at}regionh.dk
View Full Text

Citation

Kristensen LE, Keiserman M, Papp K, et al
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Publication history

  • Received June 18, 2021
  • Accepted October 11, 2021
  • First published December 15, 2021.
Online issue publication 
January 12, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.